trial
as of 2026-07-01Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
NCTId NCT00492336
at a glance
Phase 4 · Completed
Enrollment 84 (actual)
Sponsored by University of Maryland, Baltimore County
Primary completion 2012-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
84 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-01
Primary completion
2012-02
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
University of Maryland, Baltimore CountyLead Sponsor
Stanley Medical Research InstituteCollaborator
Investigators
1
Robert C Smith, M.D., Ph.DPrincipal Investigator
Sites
5 total
Baltimore, United StatesCatonsville, United StatesCatonsville, United StatesCatonsville, United StatesDundalk, United States
Facts & assertions
4 sourced
Enrollment
84
Phase
PHASE4
Primary Completion Date
2012-02
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
investigator